US FDA. FDA grants accelerated approval to first treatment for Barth syndrome [media release]. 19 Sep 2025. https://content.govdelivery.com/accounts/USFDA/bulletins/3f38219.

US FDA. FORZINITY (elamipretide) injection, for subcutaneous use. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf. Accessed 10 Nov 2025.

Sabbah HN, Taylor C, Vernon HJ. Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide. Future Cardiol. 2023;19(4):211–25.

Article  CAS  PubMed  Google Scholar 

Sabbah HN. Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide. Heart Fail Rev. 2021;26(2):237–53.

Article  CAS  PubMed  Google Scholar 

Miller PC, Ren M, Schlame M, et al. A Bayesian analysis to determine the prevalence of Barth syndrome in the pediatric population. J Pediatr. 2020;217:139–44.

Article  PubMed  Google Scholar 

Stealth BioTherapeutics. Stealth BioTherapeutics granted Fast Track designation for elamipretide for the treatment of Leber’s hereditary optic neuropathy [media release]. 18 Dec 2017. https://stealthbt.com/.

Stealth BioTherapeutics. FDA grants Rare Pediatric Disease designation to Stealth BioTherapeutics for elamipretide for the treatment of Barth syndrome [media release]. 03 Mar 2020. https://stealthbt.com/.

Stealth BioTherapeutics. Stealth BioTherapeutics granted Orphan Drug designation of elamipretide for treatment of Leber’s hereditary optic neuropathy [media release]. 30 Apr 2018. https://stealthbt.com/.

Stealth BioTherapeutics. Stealth BioTherapeutics receives Orphan Drug designation from the European Medicines Agency for elamipretide for the treatment of Barth syndrome [media release]. 01 Jun 2021. https://stealthbt.com/.

Stealth BioTherapeutics. Stealth BioTherapeutics granted Fast Track designation for elamipretide for the treatment of dry age-related macular degeneration with geographic atrophy [media release]. 10 Dec 2018. https://stealthbt.com/.

Stealth BioTherapeutics. Stealth BioTherapeutics receives FDA Fast Track designation for rare disease indication [media release]. 07 Jan 2016. https://stealthbt.com/.

Stealth BioTherapeutics. Stealth BioTherapeutics granted Orphan Drug designation of elamipretide for treatment of patients with primary mitochondrial myopathy [media release]. 02 Oct 2017. https://stealthbt.com/.

Stealth BioTherapeutics. Stealth BioTherapeutics receives Orphan Drug designation from the European Medicines Agency for elamipretide for the treatment of myopathic mitochondrial DNA depletion syndrome [media release]. 31 May 2022. https://stealthbt.com/.

United States Securities and Exchange Commission. 2021. https://www.sec.gov/Archives/edgar/data/1696396/000156459021017843/mito-20f_20201231.htm. Accessed 10 Nov 2025.

Stealth BioTherapeutics. Stealth BioTherapeutics enters into exclusive licensing agreement with Pharmanovia to commercialize elamipretide for the treatment of Barth syndrome in Europe and key global territories [media release]. 30 May 2023. https://stealthbt.com/.

Stealth BioTherapeutics. Stealth BioTherapeutics strengthens IP portfolio with issuance of U.S. patents covering elamipretide for Barth syndrome [media release]. 23 Aug 2021. https://stealthbt.com/.

Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thompson WR, Manuel R, Abbruscato A, et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024;26(7):1–10.

Article  Google Scholar 

Thompson WR, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2021;23(3):471–8.

Article  Google Scholar 

Hornby B, Thompson WR, Almuqbil M, et al. Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome. Orphanet J Rare Dis. 2022;17(1):1–9.

Article  Google Scholar 

Prasanpanich M, Husain M, Halnon NJ, et al. Cardiac pathology in a patient with a novel pathogenic variant c.703del (p.Ile235SerfsTer4) of the TAFAZZIN gene. Cardiovasc Pathol. 2025;79(107749):1–5.

Ortmann L, Velasco D, Cole J. Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report. Eur Heart J Case Rep. 2025;9(2):1–6.

Google Scholar 

Marshall M, Chase C, Lamour JM, et al. Significantly improved cardiac function in neonate with Barth syndrome on investigational drug elamipretide. J Heart Lung Transplant. 2025;44(4 Suppl):S331.

Article  Google Scholar 

Ehlers JP, Hu A, Boyer D, et al. ReCLAIM-2: a randomized phase II clinical trial evaluating elamipretide in age-related macular degeneration, geographic atrophy growth, visual function, and ellipsoid zone preservation. Ophthalmol Sci. 2025;5(1):100628.

Article  PubMed  Google Scholar 

Karaa A, Bertini E, Carelli V, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023;101(3):e238–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karaa A, Haas R, Goldstein A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90(14):e1212–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karaa A, Haas R, Goldstein A, et al. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. J Cachexia Sarcopenia Muscle. 2020;11(4):909–18.

Article  PubMed  PubMed Central  Google Scholar 

Stealth BioTherapeutics. Stealth BioTherapeutics announces achievement of 50% enrollment target in Phase 3 ReNEW study of elamipretide in patients with dry age-related macular degeneration [media release]. 13 Mar 2025. https://stealthbt.com/.